Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 338 % +111%
Debt-to-equity 114 % -12.4%
Return On Equity -685 % -5.53%
Return On Assets -319 % -13.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 917K shares -94.7%
Common Stock, Shares, Outstanding 834K shares -95.2%
Entity Public Float 7.3M USD +65.9%
Common Stock, Value, Issued 84 USD -95.1%
Weighted Average Number of Shares Outstanding, Basic 834K shares +5146%
Weighted Average Number of Shares Outstanding, Diluted 834K shares +5146%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.6M USD +22.8%
General and Administrative Expense 5.46M USD +4.33%
Operating Income (Loss) -17M USD -16.2%
Nonoperating Income (Expense) -10.1M USD -3770%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.1M USD -81.8%
Earnings Per Share, Basic 787 USD/shares +96%
Earnings Per Share, Diluted 787 USD/shares +96%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.84M USD +51.2%
Assets, Current 4.75M USD +31.5%
Property, Plant and Equipment, Net 19.9K USD -67.6%
Operating Lease, Right-of-Use Asset 37.7K USD -92.2%
Assets 5.23M USD +32.8%
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 2.97M USD +29.9%
Operating Lease, Liability, Noncurrent 38.3K USD
Liabilities 3.8M USD +66.4%
Retained Earnings (Accumulated Deficit) -84.4M USD -47.4%
Stockholders' Equity Attributable to Parent 1.43M USD -13.7%
Liabilities and Equity 5.23M USD +32.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.1M USD +21.3%
Net Cash Provided by (Used in) Financing Activities 8.85M USD +45.5%
Net Cash Provided by (Used in) Investing Activities -3.84K USD +70.3%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 834K shares -95.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.76M USD +168%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.84M USD +51.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.65K USD -31.9%
Deferred Tax Assets, Valuation Allowance 16.1M USD +27.4%
Deferred Tax Assets, Gross 16.1M USD +27.4%
Operating Lease, Liability 38.3K USD -91.5%
Depreciation 13.4K USD -58.2%
Payments to Acquire Property, Plant, and Equipment 3.84K USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 38.3K USD -91.7%
Property, Plant and Equipment, Gross 362K USD -10.6%
Operating Lease, Liability, Current 38.3K USD -90.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD -90.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03K USD -93.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.89M USD +51.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 228K USD -35.4%
Operating Lease, Payments 233K USD -33.2%
Additional Paid in Capital 85.8M USD +45.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 42K USD -62.6%
Interest Expense 17.2K USD -67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%